Search Results
Dec 10, 2025, 16:01 ET Nuvalent Appoints Ron Squarer to Board of Directors
delivering a new generation of precisely targeted therapies to patients with cancer."Mr. Squarer currently serves as the Board Chair of ADC Therapeutics and as a Board member at Travere Therapeutics. Mr. Squarer earned an M.B.A. from the Kellogg School of Management, Northwestern University,
More news about: Nuvalent, Inc.
Dec 08, 2025, 08:34 ET GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program
and high-quality biosimilars to advance next-generation biologic therapies. The company's lead program, GNX1021, is a first-in class glycan-directed ADC targeting the branched Lewis B/Y (bLeB/Y) antigen, which has demonstrated potent tumor-suppressive activity in preclinical studies and is expected to
More news about: GlycoNex, Inc.
Dec 08, 2025, 07:50 ET TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
and is in position to advance our first-in-class immune modulating bi-functional, bi-specific antibody drug conjugates (ADCs). We anticipate our lead ADC candidate to consist of a DOR inhibitor conjugated to our VISTA inhibiting antibody. TuHURA's updates at this ASH meeting demonstrate that elucidating
More news about: TuHURA Biosciences, Inc.
Dec 07, 2025, 21:00 ET Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting
proprietary technology platforms, including LeadsBody platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform), TOPiKinectics (ADC platform), which serve as the cornerstone for our continued innovation and have been validated by the clinical outcomes of our bispecific antibody portfolios.We
More news about: Leads Biolabs
Dec 07, 2025, 01:09 ET 喜訊！科倫博泰佳泰萊®、達泰萊®、科泰萊®成功納入2025國家基本醫保目錄
其第二項新增適應症獲批上市，用於治療經表皮生長因數受體酪氨酸激酶抑制劑（EGFR-TKI）和含鉑化療治療後進展的EGFR突變陽性的局部晚期或轉移性非鱗狀非小細胞肺癌（NSCLC），這也讓其成為全球首個在肺癌適應症上獲批的TROP2 ADC。此次國家基本醫保目錄公佈，蘆康沙妥珠單抗的兩項適應症均被成功納入。 蘆康沙妥珠單抗單藥治療二線及以上晚期TNBC的關鍵III期臨床研究資料顯示：（１）無進展生存期（PFS）方面，截至2023年6月21日，蘆康沙妥珠單抗的中位PFS為5.7個月，相比化療顯著延長，疾病進展或死亡風險顯著降低69%；
More news about: 科伦博泰
Dec 04, 2025, 18:38 ET Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies
next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, including the global partnership on IBI363 (PD-1/IL-2α-bias) and IBI343 (CLDN18.2 ADC), and an option for an early-stage program IBI3001 (EGFR/B7H3 ADC). Dr. Hui Zhou, Chief R&D Officer for Oncology Pipeline
More news about: Innovent Biologics
Dec 04, 2025, 08:30 ET Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium
(RW) Clinical-Multiomics Data. #PD3-02Poster Spotlight 3. December 10, 2025. 7:33-7:36 AM CSTOvercoming ADC Resistance: Payload Diversification as a Strategy for Sequential Therapy. #PD3-11Poster Spotlight 3. December 10, 2025.
More news about: Caris Life Sciences
Dec 04, 2025, 08:00 ET Network Security Market to Exceed $26 B in 2025 as SSE and WAF Lead Cloud-Delivered Expansion, According to Dell'Oro Group
Network Security Quarterly Report includes manufacturers' revenue covering the ADC, Firewall, SSE, traditional SWG appliances, and WAF product segments. Moreover, SSEs are further broken down across four primary functions: CASB, FWaaS,
More news about: Dell'Oro Group
Dec 03, 2025, 07:30 ET ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early-stage PSMA-targeting ADC.ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA
Dec 02, 2025, 16:05 ET ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early stage PSMA-targeting ADC.ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA
Dec 02, 2025, 06:40 ET Prescription Drugs Market Poised for Substantial Growth, Driven by Novel Therapies and Evolving Regulatory Landscape: Reaching US$2.15 Trillion by 2032
agreements. Notably, regulatory news included the US FDA granting Breakthrough Therapy Designation for several novel Antibody-Drug Conjugate (ADC) candidates targeting lung and breast cancers in September 2025, a quantitative marker of accelerated development. The strategic acquisition focus remains
More news about: DataM Intelligence 4 Market Research LLP
Dec 02, 2025, 04:12 ET Yatsen Group、「Beauty Innovation Insight」白書を発表
さらに2025年8月、Yatsen Groupは第35回IFSCC世界大会において本白書の英語版を発表しました。中国の化粧品R&D成果が、初めて包括的かつ国際的な査読を経た形で紹介されました。過去4年間でYatsen GroupはIFSCC、EADV、ADC、WCDといった主要な皮膚科学・化粧品学会に参加し、中国の科学的発信力を国際舞台で高めています。「ラボから市場へ」―科学を美へと変える力本白書では、Yatsen Groupが研究室で得た発見をどのように消費者価値へ転化しているかを紹介しています。グループの主力ブランド「Perfect
More news about: Yatsen Holding Limited
Dec 02, 2025, 04:00 ET Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy
has approved the investigational new drug (IND) application for the Phase Ib/II CLINCH-2 study evaluating ATG-022 (CLDN18.2 antibody-drug conjugate [ADC]) in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as well as ATG-022 in combination
More news about: Antengene Corporation Limited
Dec 01, 2025, 16:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early stage PSMA-targeting ADC.ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA
Dec 01, 2025, 10:17 ET OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting
ONC001 is a first-in-class antibody-drug conjugate (ADC) designed to uniquely target CD64, a myeloid-restricted receptor pervasively expressed in CMML and M4/M5 acute myeloid leukemia, including highly resistant subsets. The ADC was developed using OncoPrecision's proprietary discovery engine,
More news about: OncoPrecision Corporation
Dec 01, 2025, 10:17 ET OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting
ONC001 is a first-in-class antibody-drug conjugate (ADC) designed to uniquely target CD64, a myeloid-restricted receptor pervasively expressed in CMML and M4/M5 acute myeloid leukemia, including highly resistant subsets. The ADC was developed using OncoPrecision's proprietary discovery engine,
More news about: OncoPrecision Corporation
Dec 01, 2025, 10:17 ET OncoPrecision anuncia la presentación oral de ONC001, un ADC dirigido a CD64 para la leucemia monocítica
un conjugado anticuerpo-fármaco (ADC) pionero en su clase, diseñado para actuar exclusivamente sobre CD64, un receptor restringido a mieloides que se expresa ampliamente en la LMMC y la leucemia mieloide aguda M4/M5, incluyendo subpoblaciones altamente resistentes. El ADC se desarrolló utilizando el motor
More news about: OncoPrecision Corporation
Dec 01, 2025, 10:17 ET OncoPrecision gibt an, dass es auf der 67. ASH-Jahrestagung eine mündliche Präsentation zu ONC001, einem erstklassigen CD64-gerichteten ADC für monozytäre Leukämie, durchführen wird
ONC001 ist ein neuartiges Antikörper-Wirkstoff-Konjugat (ADC), das speziell auf CD64 abzielt, einen myeloischen Rezeptor, der bei CMML und akuter myeloischer Leukämie vom Typ M4/M5, einschließlich hochresistenter Subtypen, weit verbreitet ist. Das ADC wurde unter Verwendung der proprietären Forschungsplattform
More news about: OncoPrecision Corporation
Dec 01, 2025, 10:17 ET Lors de la 67e réunion annuelle de l'ASH, OncoPrecision a annoncé la présentation orale de ONC001, un conjugué anticorps-médicament ciblant le récepteur CD64, premier de sa catégorie, pour la leucémie monocytaire.
en tant que cible thérapeutique. Notre plateforme a dévoilé qu'une modalité ADC est la voie optimale pour y parvenir ».Détails de la présentation oraleTitre : ONC001 : premier ADC ciblant le récepteur CD64 pour le traitement de la leucémie monocytaire, développé
More news about: OncoPrecision Corporation
Dec 01, 2025, 08:45 ET Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium
(TAGRISSO®, AstraZeneca) an EGFR tyrosine kinase inhibitor (TKI), second-line Dato-DXd (Datroway®, AstraZeneca/Daiichi Sankyo) a Trop-2 ADC, and third-line amivantamab (Rybrevant®, Johnson & Johnson) an EGFR-cMET bispecific had sales of approximately $7 billion in 2024 with
More news about: Actinium Pharmaceuticals, Inc.
Dec 01, 2025, 08:00 ET Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer
statements relating to: the potential therapeutic value and market opportunity for the Company's ADC portfolio; the anticipated timing of the Company's development of its portfolio of ADC assets, including moving the ADC assets into the clinic; expectations regarding the beneficial characteristics, safety, efficacy,
More news about: Whitehawk Therapeutics, Inc.
Dec 01, 2025, 06:00 ET IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
this approach addresses a key unmet need by improving the durability of response to TOP1 payload-based ADC therapies. We are targeting to share additional preclinical data to support the PARG and TOP1 ADC combination rationale at a major medical conference in H1 2026," said Yujiro S. Hata, President and
More news about: IDEAYA Biosciences, Inc.
Nov 28, 2025, 08:00 ET BioDlink Showcases Europe-China CMC Collaboration Amid Developmental Breakthrough
Recognized as Biologics CDMO of the Year, BioDlink shares insights into the world's first approved EGFR-targeted ADC for recurrent/metastatic nasopharyngeal carcinomaThe company enables seamless Europe–China tech transfer and faster biologics development through an integrated,
More news about: BioDlink Biopharm Co., Ltd.
Nov 28, 2025, 00:13 ET The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
projects are in the clinical stage. The company has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 26, 2025, 12:43 ET CaliberMRI announces release of the qDisc, a new quantitative MRI phantom for added functionality of the Medium ACR Phantom
compatible with the Medium ACR phantom. CaliberMRI's qDisc (quantitative Dual Imaging Standardization Compartment) Model 141 allows sites to baseline T1, T2, ADC, and Proton Density in a single slice when scanning the Medium ACR phantom. The qDisc includes the Company's patented MR readable LC Thermometer and
More news about: CaliberMRI, Inc.